<DOC>
	<DOC>NCT02190149</DOC>
	<brief_summary>This 6-month prospective outcomes study addresses the association between timing of infusion, patient activity levels, and bleeding episodes through patient-reported measurements.</brief_summary>
	<brief_title>Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>13 to 65 years old at the time of screening has moderately severe or severe hemophilia A or B (FVIII/FIX level ≤2%), with or without transient inhibitors Hemophilia A patient currently prescribed ADVATE (FVIII) or Hemophilia B patient currently prescribed RIXUBIS (FIX) previously treated with plasmaderived FVIII/FIX concentrates or recombinant FVIII/FIX for ≥150 documented exposure days (EDs) is willing and able to comply with the requirements of the protocol is proficient in the English language to allow for use of the SPACE eDiary inhibitor titer ≥0.6 Bethesda units or currently being treated for an inhibitor has participated in another clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving a medicinal product or device during the course of this study is a family member or employee of the investigator elective major surgery is planned within 6 months after enrollment which may interfere with activities of daily living (at investigator's discretion) continuously require walking assistance devices (eg, wheelchair, crutches, etc.)</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Factor VIII Deficiency</keyword>
	<keyword>Factor FIX Deficiency</keyword>
</DOC>